miRagen Therapeutics (MGEN) PT Lowered to $1 at Wedbush, After Drug Trial Results Published
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts MGEN Hot Sheet
Price: $23.01 --0%
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 26 | Down: 19 | New: 65
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 26 | Down: 19 | New: 65
Join SI Premium – FREE
Wedbush analyst Liana Moussatos lowered the price target on miRagen Therapeutics (NASDAQ: MGEN) to $1.00 (from $6.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Titan Co Ltd (TTAN:IN) PT Lowered to INR5,540 at JPMorgan
- Pepco Group Nv (WA:PCO) PT Raised to PLN50.50 at UBS
- Tyson (TSN) PT Lowered to $56 at Piper Sandler
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Liana MoussatosSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
